A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Dry Age-related Macular Degeneration, Geographic Atrophy
In brief
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea. Up to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups: * The treatment group receiving the CPCB-RPE1 implant (up to 18 subjects). * The control group receiving a simulated "sham" implantation procedure (up to 6 subjects)
Key facts
- Study ID
- NCT06557460
- Run by
- Regenerative Patch Technologies, LLC
- People needed
- 24
- Starts
- 2025-08-01
- Expected to finish
- 2040-12-01
- Last updated by the study team
- 2026-03-25
Who can join
Age: 55 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Retina-Vitreous Associates Medical Group — Beverly Hills, California, United States (enrolling)
- Retina Associates of Southern California — Huntington Beach, California, United States (enrolling)
- USC - Keck — Los Angeles, California, United States (enrolling)
- University Retina — Lemont, Illinois, United States (enrolling)
- Retina Consultants of Texas — The Woodlands, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.